The resubmitted sBLA will include results from Study C, which evaluated biologic-naive patients with uncontrolled CSU on antihistamines.

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...

根据最近的国会交易报告，俄亥俄州第一国会选区代表Greg Landsman在过去一个月内积极交易股票。这些交易涉及多家知名公司，包括Amazon.com (NASDAQ:AMZN)、埃克森美孚 (NYSE:XOM)等。 在2024年10月15日的一系列交易中，Landsman通过Rockefeller Capital Management投资公司出售了亚马逊和埃克森美孚的股票，每笔交易价值在$15 ...

Dallas salon owner Shelley Luther discusses her comeback after being jailed for keeping her small business open during COVID ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Statement/Regulatory AdmissionAflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA15-Nov-2024 / 18:18 CET/CESTDisclosure of an inside information acc. to Article ...

At an event hosted by BioPharma Dive, drugmaker executives and investors discussed the importance of focus, smart spending ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...

A biotech startup’s journey to unicorn status hinges on its leadership and the culture fostered within the organization. A ...

Looking at options history for Regeneron Pharmaceuticals REGN we detected 8 trades. If we consider the specifics of each ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...